
Novavax to participate study comparing mixed Covid-19 vaccines
Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19… Read More















